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Introduction
Ventricular septal defects (VSD) consist of deficiencies of
the wall separating the two ventricles. VSDs are the commonest
congenital cardiac defects.1  Small VSDs rarely require
intervention, however, larger defects cause ventricular volume
overload with or without heart failure or pulmonary
hypertension and may, therefore, require closure.2 Traditionally,
closure has been an open heart surgical procedure.3 In recent
years, various devices have been developed to close a wide
variety of cardiac defects including atrial septal defects and
patent arterial ducts through transcatheter interventional
techniques.4 Recently, AGA Medical Corporation have
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introduced a range of Amplatzer VSD occluders which include
specific devices for perimembranous (PM), muscular and post
myocardial infarction (MI) VSDs. 5,6
Atrial septal defect and patent foramen ovale closure has
been carried out at St. Luke’s Hospital in Malta for the past
three years.7 This year, for the first time, we have closed three
VSDs in three individuals; two children with large
perimembranous defects and an elderly gentleman with a large
post-MI VSD. This paper will discuss this technique and initial
results.
Patients
Case 1
MB (female) was referred to out-patients due to failure to
thrive at 1 month of age. She had clinical evidence of a VSD,
confirmed by echocardiography which showed a large PM VSD
with left heart volume overload. She was commenced on caloric
supplementation and diuretics to control heart failure. She
thrived and diuretics were eventually successfully weaned off,
despite evidence of a significant defect. At 4 years of age, she
was admitted to hospital with high grade pyrexia, abdominal
pain and vomiting. She underwent an appendicectomy and
during her stay was found to have Staphylococcus aureus
septicemia. Despite adequate prophylaxis and a normal
echocardiogram during her admission, she re-presented two
weeks later with tricuspid valve endocarditis for which she was
treated with a standard six week course of antibiotics. However,
the tricuspid valve was partially eroded by a large vegetation
and remained significantly incompetent. The VSD was closed
with an Amplatzer 14mm PM VSD occluder in July 2004 at
five years of age.  Angiogram confirmed good position of the
occlusion device with a small residual left to right shunt.  She
will continue on antibiotic prophylaxis for life due to severe
tricuspid regurgitation.
Case 2
BE (male) was noted to have a murmur at routine Well
Baby Clinic follow-up. He had clinical evidence of a VSD, and
a perimembranous, subaortic VSD was diagnosed by
echocardiography. He was never in heart failure. However, he
developed cardiomegaly with a dilated left ventricle and mild
aortic regurgitation and the VSD was closed with an Amplatzer
12mm PM VSD occluder in July 2004 at 13 years of age
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Figure 1:
A - Perimembranous ventricular septal defect. Note the very
close proximity to the aortic valve.
B - Eccentric perimembranous Amplatzer VSD occluder.
C - Device in situ closing off VSD.
Angiogram confirmed good position of the occlusion device
with a small residual left to right shunt. No aortic regurgitation
was noted after the procedure on angiogram or on
echocardiogram.
Case 3
JA (male aged 76 years) has ischaemic heart disease,
congestive heart failure, chronic renal failure and diabetes
mellitus on insulin. He sustained an anterior myocardial
infarction in August 2002 as a result of which, he developed an
apical VSD that was demonstrated to be about 2 cm in diameter.
He was not deemed suitable for surgical closure of the defect
due to comorbidities and was moderately controlled with medical
treatment, albeit with severely limited exercise tolerance. His
glycaemic control was stabilized and he was started on an
infusion of N-acetyl cysteine from the morning of the procedure
and for 24 hours following the procedure as a renal sparing
measure after contrast angiography. His VSD was closed
uneventfully in July 2004 using a 24mm Amplatzer post-MI VSD
device. At catheterization, a calcific aortic valve with mild
stenosis was found. A small residual shunt from a separate hole
remained. He felt better immediately following the procedure.
All cases were done under general anaesthesia using
fluoroscopy and transoesophageal echocardiography guidance.
They were discharged on aspirin for six months to prevent over-
exuberant clotting of the devices with potential thrombus
formation on the left ventricular side of the device and risk of
transient ischaemic attack, stroke or other embolic events.
Patients should continue on antibiotic prophylaxis if there are
residual defects such as shunting across a VSD or residual
tricuspid regurgitation as in the first case or aortic stenosis as in
the third case.
Technique
A. Perimembranous defects
Deployment of these devices is under general anaesthesia
using fluoroscopy, angiography and transoesophageal
echocardiography control. The approach is from the femoral vein
and due to catheter diameters, patient weight should be above
six kilograms. The Amplatzer perimembranous VSD occluder is
a self-expandable, double disc device with discs linked together
by a connecting waist (Figure 1). The device is made from Nitinol
wire mesh (Nickel Titanium National Ordinance Ltd), a memory
alloy that returns a device to its original shape after being
collapsed into a sheath for delivery within the heart. In order to
increase its efficacy, the device is filled with three layers of Dacron
fabric. Due to the close proximity of perimembranous defects to
the aortic valve, this device is eccentric in shape with the top
rim measuring 0.5 mm and the lower rim 5 mm in order to avoid
impinging on the aortic valve. The device comes with a special
TorqVue delivery system designed specifically to deploy the
eccentric device in the correct orientation.5 The latter is
confirmed by a radio-opaque top marker that is located at the
lower end of the device.
B. Post-infarction defects
The Amplatzer post-MI VSD occluder is not eccentric and
is an extension of the Amplatzer muscular VSD occluder.
The device is circular and consists of left (4 mm diameter)
and right (3 mm diameter) discs joined together by a central
waist with is 10 mm long and with a diameter that ranges from
16 to 24 mm. Patients with acute VSD following MI are adult
patients with a thicker interventricular septum and the device
therefore has a longer waist of one centimetre.
These devices are also implanted by a transcatheter
technique through a venous or arterial or combined approach.
Because of the path and orientation that the catheter takes as it
goes through the heart, defects in the anterior outlet portion of
the septum are approached from the femoral vein, whereas
inferior or apical defects are easier to close from a jugular
approach.
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Figure 2: Fluoroscopic and angiographic depiction of steps
in VSD closure. A: Left ventriculogram showing left-to-right
shunting across a perimembranous VSD (arrow). B: Delivery
catheter from femoral vein to right ventricle across VSD to
left ventricle. The left ventricular disk has been deployed in
the left ventricle (solid arrow). The outlined arrow depicts the
radio-opaque marker that delineates the margin of the
eccentric device that must point inferiorly. C: Right ventricular
disk deployed in the right ventricle (solid arrow). D: Repeat
left ventriculogram showing almost no flow across the VSD.
Discussion
Device closure of VSD was first undertaken in 1985 using a
Rashkind double umbrella device that was initially designed for
closure of patent ductus arteriosus or atrial septal defect.8 The
Amplatzer device has only been available since 2000.9
Although both types of defects can be closed from the right
ventricular side, it is easier and safer to cross from the left
ventricular side and create an arteriovenous circuit with a guide
wire. The device is delivered left ventricular side first, followed
by the waist and followed by the right ventricular disc. The
position of the device is confirmed by transoesophageal
echocardiography and by angiography prior to release.
VSD closure relieves ventricular volume overload or frank
heart failure, reduces pulmonary hypertension and risk of
bacterial endocarditis, and may reduce the chances of the
eventual development of aortic incompetence. The advantages
of this technique include avoidance of use of heart-lung bypass
machine and blood products, and since it is done on a beating
heart, it does not produce any myocardial ischaemia. Moreover,
this technique permits the avoidance of intensive care, and
entails a short hospital stay (24 hours) with no post-operative
pain, surgical scars and other open-heart surgery complications.
This technique also gives an alternative for patients who cannot
undergo open heart surgery due to associated co-morbid
conditions.
The risks of the procedure itself are low and some of these
are similar to those encountered during routine cardiac
catheterisation. These include allergy to contrast, air or
thromboembolism with potential for cerebral ischaemia,
bleeding around introducer sheaths, disturbance to the heart
rhythm during the procedure, infection, injury to the femoral
artery, vein or nerve, and perforation of the heart. All of these
problems are very rare and similar ones may occur during open
heart surgery.  Risks specific to this procedure are interference
with the function of the aortic valve, dislodgement of the device
and incomplete closure of the defect. 5
Small residual shunts are often present immediately after
device deployment but usually close completely. If the shunt
appears large, an attempt may be made to retrieve the device
by a catheter technique, and a different device could then be
deployed, if considered appropriate. If the device cannot be
retrieved easily from the heart, cardiac surgery may be needed
for its removal and to close the VSD simultaneously. Haemolysis
after incomplete VSD closure is self-limitin g. Structural failure
of the device has not been encountered so far. The risk of heart
block is slightly higher than with surgical closure but is still
considered a low risk and may occur some weeks after device
implantation, therefore electrocardiographic follow-up is
essential.
Support from surgical colleagues, adult cardiologists and
team members of the catheterization laboratory is essential. This
new development at St. Luke’s Hospital further enhances the
services provided to cardiac patients.
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